Figure 2
Quinacrine reduces Aβ plaques and astrocytosis. (a) Time course of the in vivo experiments. Quinacrine was administered for 6 weeks intravenously, and the brains were collected for immunostaining and immunoblotting assays. (b) The colored boxes indicate the regions of brain images in (d). Blue: regions of brain images in lanes 1, 2, 3 in (d); red: HP; yellow: CTX. (c) Representative immunostaining images of Aβ deposition. 6E10 antibody was used for the visualization of Aβ plaques. Scale bars = 1 mm. (d) Representative immunostaining images of Aβ deposition and astrocytosis. Aβ was stained with the 6E10 antibody, and the level of astrocytosis was monitored using GFAP antibody. CTX and HP merge images are enlarged images of respective brain regions. Scale bars = 500 µm, 150 µm. (e) Number of plaques and (f) plaque size in whole brain area, cortex, and hippocampus. The plaque sizes of non-treated mice brains were normalized to 100%. Data are presented as ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA followed by Bonferroni’s post hoc comparisons tests). QC, quinacrine; i.v., intravenous injection; CTX, cortex; HP, hippocampus.
